People with overweight or obese have an increased risk of developing heart failure and
atrial fibrillation but treatment strategies for this group of patients remain not established …

Background Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

The glucagon-like peptide 1 receptor (GLP-1R) agonist semaglutide is effective for the
treatment of obesity and type 2 diabetes mellitus (T2DM). The purpose of this article is to …

A study presented at the American College of Cardiology's Annual Scientific Session found
that semaglutide, a medication used to treat type 2 diabetes, can improve functional status …

Previous studies have shown the efficacy and effectiveness of semaglutide to help to reduce
major adverse cardiac events (MACE) such as heart attacks and strokes for people with …

Background Heart failure with preserved ejection fraction is increasing in prevalence and is
associated with a high symptom burden and functional impairment, especially in persons …

Semaglutide in obesity-related heart failure with preserved ejection fraction Page 1
Semaglutide in obesity-related heart failure with preserved ejection fraction Semaglutide versus …

Background More women than men have heart failure with preserved ejection fraction
(HFpEF). Objectives The purpose of this study was to assess baseline characteristics and …

BACKGROUND: Patients with heart failure (HF) with preserved ejection fraction (HFpEF)
and obesity experience a high burden of symptoms and functional impairment, and a poor …

Background Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse
cardiovascular events (MACE) in people with overweight or obesity, but the effects of this …